       Document 0344
 DOCN  M9630344
 TI    CD30-mediated signaling promotes the development of human T helper type
       2-like T cells.
 DT    9603
 AU    Del Prete G; De Carli M; D'Elios MM; Daniel KC; Almerigogna F; Alderson
       M; Smith CA; Thomas E; Romagnani S; Division of Clinical Immunology and
       Allergy, University of; Florence, Italy.
 SO    J Exp Med. 1995 Dec 1;182(6):1655-61. Unique Identifier : AIDSLINE
       MED/96096439
 AB    We have recently shown that CD30, a member of the tumor necrosis
       factor/nerve growth factor receptor superfamily, is preferentially
       expressed by human T cell clones producing T helper (Th) type 2
       cytokines. We report here that costimulation with an agonistic anti-CD30
       monoclonal antibody enhanced antigen (Ag)-induced proliferation and
       cytokine secretion by established human Th2 and Th0 clones. Moreover,
       costimulation of peripheral blood mononuclear cells with the same
       anti-CD30 monoclonal antibody resulted in the preferential development
       of Ag-specific T cell lines and clones showing a Th2-like profile of
       cytokine secretion. In contrast, early blockade in bulk culture of CD30
       ligand-CD30 interaction shifted the development of Ag-specific T cells
       towards the opposite (Th1-like) phenotype. Taken together, these data
       suggest that CD30 triggering of activated Th cells by CD30
       ligand-expressing Ag-presenting cells may represent an important
       costimulatory signaling for the development of Th2-type responses.
 DE    Antigen-Presenting Cells/PHYSIOLOGY  Antigens, CD30/*PHYSIOLOGY  Cells,
       Cultured  Cytokines/METABOLISM  Human  Immunologic Memory  Lymphocyte
       Transformation  Membrane Glycoproteins/PHYSIOLOGY  Signal Transduction
       Support, Non-U.S. Gov't  T-Lymphocyte Subsets/*IMMUNOLOGY  Th2
       Cells/*IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

